文献速递糖尿病

SGLT2抑制剂治疗2型糖尿病常规临床实践中的酮症酸中毒:斯堪的纳维亚队列与巢式病例对照研究

Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-09-01

风险因素包括高HbA1c、营养不良、既往酮症酸中毒、低BMI和近期低血糖,感染是最常见诱因。风险贯穿治疗全程,应在整个治疗期间评估并嘱患者在急性疾病和应激时暂停用药。

核心结论

  • SGLT2抑制剂相关酮症酸中毒风险因患者特征差异很大,且不局限于治疗早期,应在整个治疗期间评估风险。

研究设计与样本

  • 基于瑞典、丹麦和挪威三国全国登记数据的队列和巢式病例对照研究。
  • 纳入282 282例2型糖尿病患者的322 597个SGLT2抑制剂治疗周期,年龄≥18岁。
  • 巢式病例对照按年龄、性别、出生地区、日历时间和治疗开始后时间匹配。

主要发现

  • 风险在治疗开始后不久最高,但持续贯穿整个随访期。

临床怎么用

  • 对使用SGLT2抑制剂的2型糖尿病患者应在整个治疗期间评估酮症酸中毒风险,而非仅关注治疗早期。
  • 应识别高HbA1c、营养不良、既往酮症酸中毒、低BMI和近期低血糖等高危患者。
  • 应告知患者在急性疾病和应激期间暂停SGLT2抑制剂治疗。

局限性

  • 某些短暂暴露(尤其是较轻疾病)的关联可能因对照组登记不足而被高估。
  • 探索性分析提示所观察到的关联在很大程度上是2型糖尿病患者普遍存在的,而非SGLT2抑制剂使用所特有。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SGLT2 inhibitors increase the risk of ketoacidosis, but data from routine clinical practice are scarce. We used nationwide registers with the aim of assessing the incidence, risk factors, and prognosis of ketoacidosis during SGLT2 inhibitor treatment in patients with type 2 diabetes. METHODS: In this cohort and nested case-control study we used data from three Scandinavian countries. In a cohort of SGLT2 inhibitor-treatment episodes among patients with type 2 diabetes aged at least 18 years in Sweden, Denmark, and Norway, we estimated ketoacidosis incidence. Using a nested case-control design (matched on age, sex, region of birth, calendar time, and time since treatment initiation), we assessed risk factors and precipitating or co-occurring events. Changes in diabetes medications were evaluated. FINDINGS: The study period was Jan 1, 2013, to Dec 31, 2021, in Denmark and Sweden, and Jan 1, 2013, to Dec 31, 2022, in Norway. We included 322 597 treatment episodes among 282 282 patients with type 2 diabetes (mean age 63 years, 116 521 [36·1%] of 322 597 women). During a median (IQR) follow-up of 1·3 (0·7-2·8) years, 1452 ketoacidosis events occurred (incidence 2·43 per 1000 person-years). Although highest shortly after initiation, risk persisted throughout follow-up. Strong risk factors included high HbA1c (≥83 vs ≤52 mmol/mol: odds ratio [OR] 15·37 [95% CI 11·50-20·53]), malnutrition (OR 10·54 [7·32-15·18]), previous ketoacidosis (OR 10·40 [7·09-15·24]), low BMI (<20 kg/m2vs 20 to <25 kg/m2: OR 9·98 [5·68-17·53]), and recent hypoglycaemia (OR 5·22 [2·60-10·49]). Infection was the most common precipitating or co-occurring event (454 [31·8%] of 1428 vs 862 [6·1%] of 14 233 for ketoacidosis cases vs controls; OR 7·60 [6·62-8·71]). The strongest associations were observed for alcohol intoxication, acute renal events, acute abdomen, stroke, and major surgery, although associations for some transient exposures, particularly milder conditions, might have been overestimated because of under-registration among controls. Exploratory analyses suggested that the observed associations were largely general to patients with type 2 diabetes rather than specific to SGLT2 inhibitor use. At 1 year after ketoacidosis, 211 (25·1%) of 842 remained on SGLT2 inhibitors and insulin use increased from 269 (31·9%) of 842 to 615 (73·0%) of 842. INTERPRETATION: Ketoacidosis risk with SGLT2 inhibitors varies greatly by patient characteristics and is not confined to early in treatment. Risk should be assessed throughout treatment, and patients should be instructed to pause treatment during acute illness and stress. FUNDING: Region Stockholm, Swedish Society of Medicine, Karolinska Institutet.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Kadesjö E, Söderling J, Hviid A, et al. Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study. Lancet Diabetes Endocrinol. 2026. PMID: 42679839. doi:10.1016/S2213-8587(26)00162-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。